Skip to main content

Table 1 Outline of patient clinical and molecular information for the first line targeted therapies

From: Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data

ID

Sample

Targeted drug

Non-target therapy

Response

PFS

*

Rank

**

BES

***

T

N

Distant metastases

RAS

****

CC-1

Primary colorectal cancer

regorafenib

 

progressive disease

3

160

-62.1

NA

NA

NA

Mut

CC-2

Primary colorectal cancer

bevacizumab

FOLFOX

progressive disease

3

104

-0.9

3

2

Yes

Mut

CC-4

Primary colorectal cancer

panitumumab

FOLFIRI

progressive disease

2

139

-9.5

4

2

No

WT

CC-5

Primary colorectal cancer

bevacizumab

FOLFIRI

progressive disease

5

81

-0.8

NA

2

Yes

Mut

CC-6

Primary colorectal cancer

cetuximab

FOLFIRI

progressive disease

3

90

-2.6

4

2

Yes

WT

CC-18

Primary colorectal cancer

cetuximab

XELOX

progressive disease

8

137

-9.3

3

1

Yes

WT

CC-34

Primary colorectal cancer

bevacizumab

FOLFOX

progressive disease

4

19

4.4

4

2

Yes

Mut

CC-35

Liver metastasis

bevacizumab

FOLFIRI

partial response

12

54

0.1

3

1

Yes

WT

CC-41

Liver metastasis

bevacizumab

FOLFOX

stable disease

9

5

7.9

4

0

No

WT

CC-44

Primary colorectal cancer

bevacizumab

FOLFOX

stable disease

11

2

23.5

3

0

Yes

WT

CC-45

Peritoneal metastasis

bevacizumab

FOLFIRINOX

stable disease

20

13

5.1

4

1

Yes

Mut

CC-64

Brain metastasis

bevacizumab

FOLFIRI

progressive disease

5

6

24.3

3

0

Yes

WT

CC-65

Primary colorectal cancer

bevacizumab

FOLFIRINOX

partial response

6

22

3.1

4

2

Yes

Mut

CC-72

Liver metastasis

aflibercept

FOLFIRI

progressive disease

3

166

-107.9

3

2

Yes

Mut

CC_91

Small Intestine metastasis

bevacizumab

capecitabine

stable disease

13

6

9.0

3

1

Yes

Mut

CC-94

Adrenal Gland metastasis

bevacizumab

FOLFIRI

partial response

5

27

6.6

3

1

Yes

WT

CC-95

Liver metastasis

bevacizumab

FOLFOX

progressive disease

4

99

0.3

3

1

Yes

WT

CC-105

Primary colorectal cancer

regorafenib

 

progressive disease

3

113

-3.0

3

1

Yes

WT

CC-107

Primary colorectal cancer

bevacizumab

FOLFOX

stable disease

4

22

1.7

3

2

Yes

Mut

CC-109

Peritoneal metastasis

bevacizumab

FOLFIRI

stable disease

8

1

15.7

4

0

Yes

WT

CC-111

Peritoneal metastasis

bevacizumab

FOLFOX

progressive disease

2

165

-18.3

3

0

Yes

Mut

  1. * Progression-free survival
  2. ** Rank of Oncobox Balanced Efficiency Score for a given targeted drug in a patient
  3. *** Balanced Efficiency Score of a drug
  4. **** Presence of known activating mutations in KRAS or HRAS